Literature DB >> 24833353

Bone marrow T-cell infiltration during acute GVHD is associated with delayed B-cell recovery and function after HSCT.

Angela Mensen1, Korinna Jöhrens2, Ioannis Anagnostopoulos2, Sonya Demski1, Maike Oey3, Andrea Stroux4, Philipp Hemmati5, Jörg Westermann5, Olga Blau5, Friedrich Wittenbecher5, Kamran Movassaghi6, Martin Szyska7, Sybill Thomas3, Bernd Dörken5, Carmen Scheibenbogen8, Renate Arnold5, Il-Kang Na9.   

Abstract

B-cell immune dysfunction contributes to the risk of severe infections after allogeneic hematopoietic stem cell transplantation (allo-HSCT). Delayed B-cell regeneration is found in patients with systemic graft-versus-host disease (GVHD) and is often accompanied by bone marrow (BM) suppression. Little is known about human BM GVHD. We analyzed the reconstitution kinetics of B-cell subsets in adult leukemic patients within 6 months after allo-HSCT. B-cell deficiency already existed before transplant and was aggravated after transplant. Onset of B-cell reconstitution characterized by transitional B-cell recovery occurred either early (months 2-3) or late (from month 6 on) and correlated highly positively with reverse transcription-polymerase chain reaction quantified numbers of κ-deleting recombination excision circles (KRECs). Delayed recovery was associated with systemic acute GVHD and full-intensity conditioning therapy. Histological analysis of BM trephines revealed increased T-cell infiltration in late recovering patients, which was associated with reduced numbers of osteoblasts. Functionally, late recovering patients displayed less pneumococcal polysaccharide-specific immunoglobin M-producing B cells on ex vivo B-cell activation than early recovering patients. Our results provide evidence for acute BM GVHD in allo-HSCT patients with infiltrating donor T cells and osteoblast destruction. This is associated with delayed B-cell reconstitution and impaired antibody response. Herein, KREC appears suitable to monitor BM B-cell output after transplant.
© 2014 by The American Society of Hematology.

Entities:  

Mesh:

Year:  2014        PMID: 24833353     DOI: 10.1182/blood-2013-11-539031

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  29 in total

Review 1.  Aberrant B-cell homeostasis in chronic GVHD.

Authors:  Stefanie Sarantopoulos; Jerome Ritz
Journal:  Blood       Date:  2015-02-02       Impact factor: 22.113

2.  The importance of bone marrow involvement in GVHD.

Authors:  Caroline A Lindemans; Alan M Hanash
Journal:  Blood       Date:  2014-08-07       Impact factor: 22.113

3.  Post-transplantation cyclophosphamide restores early B-cell lymphogenesis that suppresses subsequent chronic graft-versus-host disease.

Authors:  Miki Iwamoto; Shuntaro Ikegawa; Takumi Kondo; Yusuke Meguri; Makoto Nakamura; Yasuhisa Sando; Hiroyuki Sugiura; Yuichi Sumii; Noboru Asada; Daisuke Ennishi; Hisakazu Nishimori; Keiko Fujii; Nobuharu Fujii; Misako Shibakura; Yoshinobu Maeda; Ken-Ichi Matsuoka
Journal:  Bone Marrow Transplant       Date:  2020-10-30       Impact factor: 5.483

4.  The enteric virome in hematopoietic stem cell transplantation: ready for its close-up.

Authors:  Shuichiro Takashima; Alan M Hanash
Journal:  Nat Med       Date:  2017-09-08       Impact factor: 53.440

Review 5.  B cells in chronic graft-versus-host disease.

Authors:  William McManigle; Ayman Youssef; Stefanie Sarantopoulos
Journal:  Hum Immunol       Date:  2019-03-05       Impact factor: 2.850

6.  Increased GVHD-related mortality with broad-spectrum antibiotic use after allogeneic hematopoietic stem cell transplantation in human patients and mice.

Authors:  Marcel R M van den Brink; Robert R Jenq; Yusuke Shono; Melissa D Docampo; Jonathan U Peled; Suelen M Perobelli; Enrico Velardi; Jennifer J Tsai; Ann E Slingerland; Odette M Smith; Lauren F Young; Jyotsna Gupta; Sophia R Lieberman; Hillary V Jay; Katya F Ahr; Kori A Porosnicu Rodriguez; Ke Xu; Marco Calarfiore; Hendrik Poeck; Silvia Caballero; Sean M Devlin; Franck Rapaport; Jarrod A Dudakov; Alan M Hanash; Boglarka Gyurkocza; George F Murphy; Camilla Gomes; Chen Liu; Eli L Moss; Shannon B Falconer; Ami S Bhatt; Ying Taur; Eric G Pamer
Journal:  Sci Transl Med       Date:  2016-05-18       Impact factor: 17.956

7.  Impaired bone marrow B-cell development in mice with a bronchiolitis obliterans model of cGVHD.

Authors:  Oleg V Kolupaev; Trisha A Dant; Hemamalini Bommiasamy; Danny W Bruce; Kenneth A Fowler; Stephen L Tilley; Karen P McKinnon; Stefanie Sarantopoulos; Bruce R Blazar; James M Coghill; Jonathan S Serody
Journal:  Blood Adv       Date:  2018-09-18

Review 8.  The Biology of Chronic Graft-versus-Host Disease: A Task Force Report from the National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease.

Authors:  Kenneth R Cooke; Leo Luznik; Stefanie Sarantopoulos; Frances T Hakim; Madan Jagasia; Daniel H Fowler; Marcel R M van den Brink; John A Hansen; Robertson Parkman; David B Miklos; Paul J Martin; Sophie Paczesny; Georgia Vogelsang; Steven Pavletic; Jerome Ritz; Kirk R Schultz; Bruce R Blazar
Journal:  Biol Blood Marrow Transplant       Date:  2016-10-03       Impact factor: 5.742

9.  CD40 Activity on Mesenchymal Cells Negatively Regulates OX40L to Maintain Bone Marrow Immune Homeostasis Under Stress Conditions.

Authors:  Barbara Bassani; Claudio Tripodo; Paola Portararo; Alessandro Gulino; Laura Botti; Claudia Chiodoni; Elena Jachetti; Niccolò Bolli; Marilena Ciciarello; Korinna Joehrens; Ioannis Anagnostopoulos; Il-Kang Na; Antonio Curti; Mario P Colombo; Sabina Sangaletti
Journal:  Front Immunol       Date:  2021-05-18       Impact factor: 7.561

10.  Memory B-cell reconstitution following allogeneic hematopoietic stem cell transplantation is an EBV-associated transformation event.

Authors:  David M Burns; Rose Tierney; Claire Shannon-Lowe; Jo Croudace; Charlotte Inman; Ben Abbotts; Sandeep Nagra; Christopher P Fox; Sridhar Chaganti; Charles F Craddock; Paul Moss; Alan B Rickinson; Martin Rowe; Andrew I Bell
Journal:  Blood       Date:  2015-10-08       Impact factor: 25.476

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.